Polymyxin B
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Polymyxin B: From Gram-Negative Bacterial Infections to Bronchitis
One-Sentence Summary
Polymyxin B is a polypeptide antibiotic classically used against serious multidrug-resistant gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii); a documented South African indication record is not currently available in this evidence pack. The TxGNN model predicts it may be effective for Bronchitis, but the supporting evidence is currently limited to 0 clinical trials and 14 publications, several of which describe inhaled Polymyxin B inducing bronchoconstriction rather than treating it. This is a low-confidence, early-stage signal, not a validated repurposing candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the regulatory data provided (drug not currently marketed in South Africa); pharmacologically known as an antibacterial agent for serious gram-negative infections |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L4 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Polymyxin B is a cyclic lipopeptide antibiotic that disrupts the outer membrane of gram-negative bacteria, and its efficacy against multidrug-resistant gram-negative pathogens (particularly Pseudomonas aeruginosa and Acinetobacter baumannii) in serious infections such as ventilator-associated pneumonia and tracheobronchitis has been documented in the collected literature. Mechanistically, this antibacterial activity could extend to bacterial bronchitis caused by the same pathogens.
However, the evidence for this specific indication is mixed in direction. A meaningful share of the identified publications (e.g., PMIDs 231152, 2984629, 7402949, 4322737) do not evaluate Polymyxin B as a treatment for bronchitis at all — they use inhaled Polymyxin B as a bronchial provocation agent to induce bronchoconstriction in asthma/COPD research, and one report is explicitly titled “Danger of polymyxin B inhalation.” Only a smaller subset (PMIDs 23124906, 17350201, 4319158, 4373513) describe therapeutic use of Polymyxin B (endobronchial/inhaled) against gram-negative tracheobronchitis, and these are small cohort or case-series studies without controlled comparison. The mechanistic rationale is therefore plausible for a narrow subset of Pseudomonas-related bronchitis, but the aggregate literature signal is not clearly supportive and includes a real safety concern regarding inhalation-induced bronchospasm.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23124906 | 2013 | Cohort | Infection | Compared Polymyxin B with other antimicrobials for ventilator-associated pneumonia and tracheobronchitis (VAT) caused by P. aeruginosa or A. baumannii |
| 17350201 | 2007 | Cohort | Diagnostic Microbiology and Infectious Disease | Inhaled Polymyxin B used as salvage/initial treatment for pneumonia and tracheobronchitis from multidrug-resistant gram-negative bacilli in 19 patients |
| 4319158 | 1970 | Case Series | Chest | Endobronchial Polymyxin B evaluated in patients with chronic bronchitis |
| 4373513 | 1974 | Case Series | Journal of the Kansas Medical Society | Systemic gentamicin plus Polymyxin B aerosol used for Pseudomonas tracheobronchitis |
| 231152 | 1979 | Provocation Test (Adverse) | Lung | Inhaled Polymyxin B tested for bronchial reactivity in asthma and chronic obstructive bronchitis — measures induced bronchoconstriction, not treatment effect |
| 2984629 | 1985 | Provocation Test (Adverse) | Orvosi Hetilap | Polymyxin B sulfate used to induce non-specific bronchial provocation in asthma/chronic bronchitis |
| 7402949 | 1980 | Provocation Test (Adverse) | Pneumonologia Polska | Compared exercise-induced bronchospasm with histamine/Polymyxin B provocation testing in asthma and chronic obstructive bronchitis |
| 4322737 | 1971 | Case Report (Adverse) | Annals of Internal Medicine | Reports a hazard of Polymyxin B inhalation (adverse respiratory event) |
| 8054833 | 1994 | Animal Model | Clinical Autonomic Research | Guinea-pig model of eosinophilic bronchitis induced by intranasal Polymyxin B, used to study cough mechanisms |
| 28441858 | 2017 | Animal Model | Zhonghua Yi Xue Za Zhi | Mouse model of eosinophilic bronchitis using Polymyxin B, examining eosinophil activation and airway hyperresponsiveness |
South Africa Market Information
No SAHPRA registrations were identified for Polymyxin B in the data available for this review (0 licenses on record; market status: Not Marketed). Regulatory status should be independently confirmed with SAHPRA before any clinical use is considered.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: Warnings/contraindications and formal drug interaction data for Polymyxin B were not resolvable from the current evidence sources (flagged internally as a Blocking data gap), so no drug-specific safety statements can be made pending PI retrieval.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level is L4 (preclinical/mechanistic and small uncontrolled studies only), with no registered clinical trials for bronchitis, and a substantial portion of the literature actually documents inhaled Polymyxin B causing bronchoconstriction rather than treating bronchitis — the signal is mechanistically plausible only for a narrow, pathogen-specific subset and is not ready to progress.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI) — warnings, contraindications, and drug interaction data (currently a Blocking data gap)
- Confirmed mechanism-of-action documentation (currently a Data Gap)
- A prospectively designed, controlled study of Polymyxin B (systemic or inhaled) specifically in gram-negative bacterial bronchitis, with bronchospasm risk as a monitored safety endpoint
- Clarification of South African market/import status, since there are currently 0 SAHPRA registrations
Note for reviewers: Within this same evidence pack, conjunctivitis (rank 3, TxGNN score 99.06%) has substantially stronger evidence — L1, three clinical trials including a completed Phase 4 RCT, and 20 supporting publications — reflecting that Polymyxin B/Trimethoprim (Polytrim) is already an established bacterial conjunctivitis therapy elsewhere. If the goal is to identify the best-supported repurposing candidate for Polymyxin B rather than strictly the top TxGNN-ranked one, conjunctivitis warrants a separate, dedicated evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.